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Data are accumulating that emphasize the important role of the intestinal barrier and intestinal permeability for
health and disease. However, these terms are poorly defined, their assessment is a matter of debate, and their
clinical significance is not clearly established. In the present review, current knowledge on mucosal barrier and its
role in disease prevention and therapy is summarized. First, the relevant terms ‘intestinal barrier’ and ‘intestinal
permeability’ are defined. Secondly, the key element of the intestinal barrier affecting permeability are described.
This barrier represents a huge mucosal surface, where billions of bacteria face the largest immune system of our
body. On the one hand, an intact intestinal barrier protects the human organism against invasion of
microorganisms and toxins, on the other hand, this barrier must be open to absorb essential fluids and nutrients.
Such opposing goals are achieved by a complex anatomical and functional structure the intestinal barrier consists
of, the functional status of which is described by ‘intestinal permeability’. Third, the regulation of intestinal
permeability by diet and bacteria is depicted. In particular, potential barrier disruptors such as hypoperfusion of the
gut, infections and toxins, but also selected over-dosed nutrients, drugs, and other lifestyle factors have to be
considered. In the fourth part, the means to assess intestinal permeability are presented and critically discussed. The
means vary enormously and probably assess different functional components of the barrier. The barrier assessments
are further hindered by the natural variability of this functional entity depending on species and genes as well as
on diet and other environmental factors. In the final part, we discuss selected diseases associated with increased
intestinal permeability such as critically illness, inflammatory bowel diseases, celiac disease, food allergy, irritable bowel
syndrome, and – more recently recognized – obesity and metabolic diseases. All these diseases are characterized by
inflammation that might be triggered by the translocation of luminal components into the host. In summary, intestinal
permeability, which is a feature of intestinal barrier function, is increasingly recognized as being of relevance for health
and disease, and therefore, this topic warrants more attention.
Keywords: Intestinal barrier, Intestinal permeability, Microbiota, Tight junctions, Obesity, Inflammatory bowel disease,
Irritable bowel syndrome, Prebiotics, Probiotics, Gut healthIntroduction
Why do we need a gut barrier? The intestinal barrier
covers a surface of about 400 m2 and requires approxi-
mately 40% of the body’s energy expenditure. It prevents
against loss of water and electrolytes and entry of antigens
and microorganisms into the body [1] while allowing
exchange of molecules between host and environment and
absorption of nutrients in the diet. Specialized adaptations* Correspondence: bischoff.stephan@uni-hohenheim.de
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unless otherwise stated.of the mammalian intestinal mucosa fulfill two seemingly
opposing functions: firstly to allow a peaceful co-existence
with intestinal symbionts without eliciting chronic inflam-
mation and secondly to provide a measured inflammatory
and defensive response according to the threat from path-
ogens [2,3]. It is a complex multilayer system, consisting
of an external "physical" barrier and an inner "functional"
immunological barrier. The interaction of these 2 barriers
enables equilibrated permeability to be maintained [4]. To
understand this complex barrier, not only the functions of
its components, but also the processes of interactions of
bacterial and other luminal components with cells andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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data showed that disruption of the peaceful co-existence
with intestinal symbionts at early life, and possibly even
later in life, results in severe immunodeficiency and risk of
disease [5-7]. Such findings support the hypothesis that
the breakdown of intestinal barrier control mechanisms
means danger and possibly disease.
What is the difference between intestinal barrier and
intestinal permeability? The two terms have been used
synonymously although they probably do not mean the
same thing. A clear definition of such parameters as
means to assess them is mandatory to avoid future con-
fusion and to assess their impact for disease prevention
and disease. In fact, intestinal permeability is a barrier
feature closely linked to the intestinal commensal micro-
biota as well as to the elements of the mucosal immune
system (Figure 1). Many factors can alter intestinal per-
meability such as gut microbiota modifications, mucus
layer alterations, and epithelial damage, resulting in
translocation of luminal content to the inner layers of
the intestinal wall. Moreover, lifestyle and dietetic factors
like alcohol and energy-dense food can increase intes-
tinal permeability such as alcohol and energy-dense
Western style diet [8-10].
What is the clinical significance of the intestinal barrier
and intestinal permeability? There is now increasing evi-
dence for the notion that loss of intestinal barrier func-
tions can occur either abruptly, e.g. following a major
trauma resulting in gram-negative sepsis and multi-organ
failure (MOF), or gradually leading to chronic inflamma-
tory diseases. During the last 30 years, almost 2000 publi-
cations appeared according to the PubMed database with
a linear increase from approximately 10 publications a year
in the eighties of last century to almost 100 at present. Al-
though we learned over the past decade about the link
between the intestinal barrier and diseases, the mecha-
nisms are not precisely understood. For example, we have
limited knowledge of what causes initially intestinal barrier
dysfunction, and what prevents or restores it. The formerFigure 1 Relation between intestinal permeability, intestinal
microbiota, and mucosal immunology. For details see text.might involve different events including virus infections,
reduced perfusion of the mucosa, drugs, or changes in the
microbiota [6]. New data suggest that intestinal barrier and
intestinal microbiota play a role in many different diseases
such as idiopathic liver fibrosis or intestinal dysbiosis the
mechanism of which were largely unclear until recently
[11-13].
Understanding that the intestinal barrier also means to
have clear definitions, clear modes of assessment in vitro
and in vivo in animal models and in humans, and clear
strategies of how to perform human trials in this field.
These topics have been extensively discussed within an ex-
pert panel in Frankfurt/Germany in June 2012. The major
results are summarized and extended in the following text.
Review
Definition of intestinal permeability
Definition of intestinal permeability and intestinal barrier
The term "mucosal barrier" was adopted by Cummings in
2004 to describe the complex structure that separates the
internal milieu from the luminal environment [14]. The
physical barrier includes a cellular component consisting
of the vascular endothelium, the epithelial cell lining, and
the mucus layer. Next to this physical barrier, chemical
substances take part in the barrier function as well. They
consist of digestive secretions, immune molecules, cell
products like cytokines, inflammatory mediators and anti-
microbial peptides, mainly produced by Paneth cells in
the crypts of the small intestine. The intestinal microbiota
is involved in metabolic processes and modulates the bar-
rier, but does not represent a barrier function per se. On
the other hand, the microbiota contributes to "intestinal
health" - a term that is increasingly used although poorly
defined. It may be described as a state of physical and
mental well-being in the absence of gastro-intestinal com-
plaints that require the consultation of a doctor, in the
absence of indications of or risks for bowel disease and in
the absence of confirmed bowel disease [6].
The terms “intestinal barrier” and “intestinal permeabil-
ity” describe two different aspects of the same anatomical
structure, the intestinal wall composed of four layers, the
mucosa, the submucosa, the muscularis and the serosa.
“Intestinal permeability” is a term shaped preferentially by
electrophysiologists studying epithelial permeability in
Ussing chambers using tissue explants from animals or
humans for research purposes [15,16]. By extrapolating
the Ussing chamber experiments to the in vivo situations,
particular permeability tests have been developed such as
the sugar test [17]. All these tests have in common that
defined molecules such as electrolytes or sugars of differ-
ent molecular weight are used for their capacity to enter
and cross the epithelium or the mucosal layer, respectively
and finally entering the submucosal site (Ussing chamber)
or the blood (sugar test).
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more recently by gastroenterologists, immunologists and
microbiologists to emphasize the protective component of
the gut shielding us against bacterial invasion, or invasion
of other microorganisms and their toxins. Therefore, the
means of assessing barrier functions were different to the
approaches by the electrophysiologists and consisted of
measuring translocation of bacteria or bacterial products
like endotoxin from the gut into the portal vein, the liver
or the systemic bloodstream. Likely, the mechanisms
determining electrolyte fluxes, carbohydrate permeability
and bacterial translocation are quite different; however, all
approaches have in common that transfer of defined mol-
ecules across the intestinal wall (or parts of it) are mea-
sured. This knowledge might provide a basis for a
definition of intestinal permeability, and also of normal
and pathological intestinal permeability (Table 1).
Thus, according to the proposed definitions, intestinal
permeability can be understood as a measurable feature
of the intestinal barrier. The proposed definitions are
related to above mentioned definition of gut health
thought to be closely related to the intestinal barrier and
intestinal permeability [1,6].
The proposed definitions extent the more descriptive
approach by Cummings et al. [14], who summarized: (1)
The mucosal barrier is a complex structure that separates
the internal milieu from the luminal environment. (2)
Physically, the barrier includes cellular and stromal compo-
nents, from the vascular endothelium to the epithelial cell
lining, and the mucus layer, which consists of a gel formed
by the interaction of various mucosal secretions, namely
mucins, trefoil peptides and surfactant lipids. (3) Apart
from the physical barrier, a chemical barrier exists consist-
ing of digestive secretions, antimicrobial peptides, and other
cell products (cytokines, inflammatory mediators etc.). (4)
Also the intestinal microbiota can be considered as a
barrier. (5) Finally immune functions and motility contribute
to the barrier.
Key element of the intestinal barrier affecting intestinal
permeability
In recent times, several important molecules and mecha-
nisms of the intestinal barrier could be identified (Figure 2).Table 1 Definitions
Intestinal barrier is a functional entity separating the gut lumen fro
layer), humoral elements (defensins, IgA), immunu
neurological elements
Intestinal permeability is defined as a functional feature of the intestinal
intestinal wall as a whole or across wall compone
can be adequately measured in these settings
Normal intestinal
permeability




is defined as a disturbed permeability being non-t
of intestinal homeostasis, functional impairmentsA single layer of epithelial cells form the main physical bar-
rier between the lumen and mucosal tissues. The paracellu-
lar space is sealed by tight junctions (TJ) which regulate the
flow of water ions and small molecules through the com-
position of claudins and other proteins in the junctional
complex [5,18,19]. Below the tight junctions are the adher-
ence junctions (AJ), which are important in cell-cell signal-
ing and epithelial restitution as well as desmosomes
supporting epithelial stability. TJ complexes consist of
intra-membrane proteins, occludin and different members
of the claudin family depending on the tissue and location
that interlink within the paracellular space. Occludin and
claudins and tricellulin link adjacent cells to the actin cyto-
skeleton through cytoplasmatic scaffolding proteins like
Zonula occludens proteins [5]. Tricullin and occludin as
well as a new protein named marvelD3, can be replaced
in part by each other, but if all three are down-regulated
or lacking, severe leakage occurs [20]. Claudins are a
family of tight junction proteins consisting of sealing
molecules and pores facilitating water and electrolyte
loss. Zonula occludens proteins (ZO-1, ZO-2 and ZO-3)
are important intracellular tight junction proteins, link-
ing the cell cytoskeleton to the transmembrane tight
junction proteins.
Whereas occludin and junction adhesion molecule have
a regulatory role, claudins are transmembrane proteins
mainly responsible for the intestinal barrier function. A
central regulator of this epithelial barrier is the intestinal
microbiota [21]. The importance of intact epithelial TJ is
demonstrated again in inflammatory bowel diseases (IBD)
[16,22]. For example, investigations in patients with
Crohn's disease (CD) indicated impaired TJ complexity in
sigmoid colon biopsies accompanied by a reduced expres-
sion of sealing claudin-3, −5 and −8 and occludin as well
as a re-distribution of claudin-5 and −8 off the TJ [23].
Analogous changes were observed in ulcerative colitis
(UC), comprising down-regulation of claudin-1 and −4 and
occludin, but up-regulation of pore-forming claudin-2 [24].
The intestinal epithelium is renewed approximately
every 5 days in humans due to proliferation and differenti-
ation of multipotential stem cells located in the crypts of
Lieberkühn [25]. At the tips of the villus and epithelial
surface in the colon the fully differentiated cells undergom the inner host, and consisting of mechanical elements (mucus, epithelial
nological elements (lymphocytes, innate immune cells), muscular and
barrier at given sites, measurable by analyzing flux rates across the
nts of defined molecules that are largely inert during the process and that
y individuals with no signs of intoxication, inflammation or impaired
ransiently changed compared to the normal permeability leading to a loss
and disease
Figure 2 Chemical and physical barriers in the intestine. For
explanations see text.
Figure 3 Cell shedding leading to a temporary epithelial
defect. Outwardly directed flow of fluorescein through a epithelial
defect created by incomplete sealing of a gap created by cell
shedding. Image obtained by confocal laser endomicroscopy of a
patient with small bowel Crohn’s disease.
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cells can differentiate into 4 cell linages, namely enterocytes,
enteroendocrine cells, mucus producing goblet cells and
Paneth cells which are only found in the human small intes-
tine [26]. Goblet cells secrete mucin which is heavily glyco-
sylated and polymerized into a enormous net-like structure.
Mucin 2 is the major component of secreted mucin in the
large and small intestine and plays a key role in keeping
intestinal microbes at a distance from the epithelial surface.
Colonization by commensal intestinal microbiota is lim-
ited to an outer "loose" mucus layer, and interacts with the
diverse oligosaccharides of mucin glycoproteins, whereas
an "inner" adherent mucus layer is largely devoid of bacteria
[27]. In both experimental models of IBD and in humans
the mucus layer becomes more permeable to bacteria and
is therefore considered critical etiological factors in this dis-
ease and possibly other intestinal disorders [28]. In addition
to the surface mucins the apical surface of the epithelium is
protected by a glycocalyx made up of membrane tethered
mucins. These are also glycosylated and are released upon
binding by microorganisms as a defense mechanism to
prevent colonization [29,30].
It has recently been recognized that sites of cell shed-
ding represent a third site for the physical intestinal bar-
rier. The intestinal epithelium is one of the most dynamic
in the body with epithelial cells arising from stem cells at
crypt bases, migrating to the villus tip in the case of the
small intestine and the colonic surface from where they
are shed. This cellular extrusion process could potentially
compromise the integrity of the epithelium. Recent studies
have shown that under physiological healthy conditions
epithelial extrusion is triggered by stretching of the epithelial
cell, which is detected by activation of the stretch-sensitive
cation channel Piezo [31]. This triggers a signal transduction
pathway involving the sphingosine 1 kinase, the S1P receptor
and Rho kinase [32]. This pathway triggers by a redistribu-
tion of proteins from the tight junction to surround the
shedding cell and to fill the gap left after extrusion is com-
pleted thereby maintaining the barrier [33]. This mechanismappears to be very robust such that the barrier rarely fails at
sites of cell shedding.
Inflammatory cytokines such as TNFα usually increase
the rate of cell shedding. Under these circumstances, the
redistribution of the tight junction does not always seal
the gap left by shedding cells. This is frequently observed
because more than one epithelial cell is shed from one site
leaving a gap that is too large to be plugged by the redistri-
bution of tight junction proteins [34].
An important point is the direction of flow through gaps
that are not sealed can be either into or out of the intes-
tinal wall. Local pressure, electrochemical and osmotic gra-
dients determine the direction of flow. In contrast to the
tight junction the defects at cell shedding sites are too wide
to permit local inwardly directly osmotic gradients to be
generated. Instead the direction of flow is determined by
the balance of inwardly directed osmotic and electrochem-
ical gradients between the lumen and the subepithelium
and outwardly directed hydrostatic gradients generated by
hydrostatic pressure and peristalsis (Figure 3). There is a
positive hydrostatic pressure in the subepithelium. The
direction of flow is thus highly labile and can be readily
changed by alterations of osmolarity of the luminal contents
as will occur during the mixing as the food travels down the
intestine [35].
The mucus components of the gut barrier are fortified by
antimicrobial peptides and proteins including lysozyme.
Paneth cells produce a range of antimicrobial factors to
protect the crypt cells from infection with microorganisms
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[36,37]. Epithelial cells secrete beta-defensins some of which
are upregulated in response to sensing of microbes by
pattern-recognition receptors such as Toll-like receptors.
Ileal CD is associated with a decreased production of Paneth
alpha-defensins in response to sensing of microbes by
pattern-recognition of commensal bacteria and pathogens,
whereas colonic CD is associated with a reduced expression
of HBD1 and a reduced induction of HBD2 and HBD3 also
resulting in a reduced mucosal defense [38]. In the mouse,
there are more than 20 α-defensins (cryptidins) produced in
Paneth cells, but not in neutrophils, and these are processed
differently compared to the human system [39]. The Reg3
proteins have recently been shown to play a key role in
barrier defense. For example, mouse Reg3g and HIP/PAP
in humans has been reported to be bactericidal for Gram-
positive bacteria in vitro, and to be important in the spatial
compartmentalization of microbes in the intestine [40].
Other structures such as blood vessels, smooth muscle
cell layers and components of the enteric nervous system
(ENS) contribute to the intestinal barrier by regulating the
mucosa and by their capacity to initiate specific defense
programs in case of danger [5,6,18].
Mammals produce larger amounts of secretory immuno-
globulin A (sIgA) in the mucosa reflecting its central role in
immunity and protection against pathogens. B cell activa-
tion and proliferation leading to antigen-specific sIgA pro-
duction occurs in the gut associated lymphoid tissue
(GALT) via T cell dependent pathways [41]. In addition to
the T cell-dependent pathway for IgA production, there is a
faster mechanism for generating IgA responses to highly
conserved antigenic determinants on commensal bacteria
and pathogens [42,43]. In mice, this involves a specialized
subset of B-1 cells that can rapidly produce secretory IgA
in the absence of help from CD4+ T cells [44]. This sIgA
commonly known as ‘natural’ antibody and appears to be
bind several antigens. The repertoire of ‘natural IgA’ is
restricted and affinity maturation is limited, although the
heavy-chain variable region genes used by IgA-producing
plasma cells in the gut are somatically hyper-mutated, to
diversify antibody specificity [42]. Equivalent B-1 cells have
not been identified in humans but they may have function-
ally equivalent cells that can colonize the lymphoid tissues
and generate natural antibody [45].
Much of the IgA produced in the gut appears not to be
reactive to the commensal microbiota. Nevertheless, in
germ-free mice sIgA is present at very low levels in the gut
and increases substantially soon after colonization with
bacteria [46]. sIgA can mediate protection at mucosal sur-
faces by binding to viruses and bacteria to prevent or in-
hibit their attachment to and/or invasion of epithelial cells,
a process known as immune exclusion [47]. Additionally,
sIgA can also interact with antigens presented by intracellu-
lar pathogens in endosomes during the pIgR–mediatedtransport through epithelial cells. Recently we have begun
to appreciate its homeostatic roles of sIgA in shaping the
intestinal microbiota, preventing mucosal inflammation by
immune exclusion, removal of antigen-antibody complexes
in the LP and the neutralization of inflammatory mediators.
Serotonin, histamine and proteases
Serotonin/5-hydroxytryptamin (5-HT) produced by entero-
chromaffin cells in the intestine and histamine produced by
mucosal mast cells acts as a proinflammatory mediators in
the intestine and modulate intestinal permeability [48-51].
Our experiments in serotonin reuptake transporter (SERT)
knockout mice revealed that absence of SERT aggravates
inflammation, because mucosal 5-HT levels increase in an
uncontrolled manner. Interestingly, not only experimental
colitis is worsened in SERT-knockout mice compared to
normal littermates, but also fructose-induced endotoxin
translocation and subsequent steatosis in the liver [50].
Endogenous cannabinoid system
The plant Cannabis sativa has bee used to treat various
disorders of the gastrointestinal tract such as vomiting,
anorexia, diarrhea, and intestinal inflammation [52]. Recent
experimental data in animals indicate now that the intestinal
barrier function is regulated in vivo through activation of the
intestinal cannabinoid type 1 receptor (CB1R). CB1R, but
not CB2R, exerts a protective role in colonic permeability as
shown in CB1R knockout mice that respond to stress with
enhanced permeability compared to normal littermates [53].
Most interestingly, the gut microbiota – and possibly also
nutrients – contribute to the regulation of the intestinal
barrier via setting the tone of intestinal endocannabinoid
system. Cani et al. reported that in obese mice, CB1R is
upregulated, and treatment with a CB1R antagonist results
in reduced translocation of bacterial antigens such as lipo-
polysaccharide (LPS) into the systemic circulation [54]. The
opposing effects of cannabinoids (either improving or wors-
ening intestinal permeability) might be related to the recent
observation that endocannabinoids such as anandamide
worsen permeability while phytocannabinoids like cannabi-
diol and tetrahydrocannabidiol, which might act as (partial)
CB1R antagonists, promote protection or recovery from
intestinal permeability [52].
Regulation of intestinal permeability by diet and bacteria
Intestinal barrier and the microbiota
The intestinal tract harbors the largest bacterial community
associated with the human body, reaching densities of about
1012 bacteria per gram of luminal content in the distal colon.
Each individual carries up to a few hundred species of intes-
tinal bacteria most of which fall into two dominant phylum,
Bacteroidetes and Firmicutes [55-57]. The predominance of
certain cornerstone species in the microbiota has been pro-
posed to drive one of three preferred ecological compositions
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independent of individual host characteristics such as
body mass index, age, or gender or geographical location but
may be influenced by diet and host genetic backgrounds [59].
The intestinal microbiota is considered to be largely
symbiotic in nature and involved in various processes,
including the breakdown and absorption of nutrients, the
production of vitamins and hormones, and the prevention
of colonization by pathogens (Table 2). The gut barrier
plays a key role in the avoidance of inflammatory responses
to the microbiota and is regulated by a finely tuned network
of immune mechanisms for microbial recognition and
tolerance to the microbiota [60,61]. Failure to achieve or
maintain this equilibrium between a host and its microbiota
has negative consequences for both intestinal and systemic
health. Several diseases have been linked to changes in the
microbiota populations, or to reduction of the microbiota's
diversity, including, atopic diseases, inflammatory bowel
disease (IBD), diabetes, obesity, cancer and very recently,
even neuropathologies. Some of these pathologies are asso-
ciated with altered barrier function and increased perme-
ability of the epithelium [6,7]. The microbiota is implicated
in these physiological changes for example via reduced
numbers of butyrate producers and butyrate production
[62,63], thereby contributing to the pathophysiology of
inflammatory diseases [64]. In IBD, inflammation is also
linked to increased abundance of pathobionts such as
adherent invasive E. coli (AIEC), which can directly damage
the barrier to promote inflammatory responses [65,66].
Mucus may serve as binding sites for bacteria enabling
them to persist and colonize the surface of the mucus layer.
Several species from different phyla can grow on mucus as
a carbon source although complete degradation of mucus
depends on the concerted action of a consortium of
bacteria, due to the high degree of diversity of the mucin
oligosaccharide chains and their possible modifications.
The normal intestinal microbiota triggers the epithelium
for synthesizing mucus sugars, while selected commensal
bacteria such as Akkermansia muciniphila regulate mucus
layers by utilizing mucins as an energy source [67,68].
When microbiota are not present to degrade mucus e.g. in
germ-free rodents, mucus production and degradation are
imbalanced, leading to a doubling in the thickness of the
mucus layer and swelling of the cecum due to the accumula-
tion of mucus, and the resulting retention of water [69].
Mucin degradation has been associated with bacterial patho-
genicity as it erodes the protective mucus layer but in
relation to the microbiota it might serve as a host 'prebiotic'Table 2 Proposed functions of the human intestinal
microbiota
I Host defense against pathogens and toxins
II Development and maintenance of the intestinal immune system
III Support of digestion by supply of enzymatic capacityto stimulate growth of symbionts and shape the ecology of
the microbiota.
The intestinal barrier and bacterial pathogens
Many pathogens specifically interact with defined element
of the intestinal barrier underlining the importance of
bacterial-host interactions in both health and disease. For
example, epithelial tight junctions (TJ) can be altered by
several pathogens (Table 3). These effects may result from
direct modification of TJ proteins such as occludin, or by
different kinase mediated effects on the perijunctional
actomyosin ring [70-85]. Pathogens, as well as usage of
antibiotics, might disturb the intestinal mucus layer, either
by enhancing mucus degradation, or by inhibiting the
normal commensal triggers for mucus production [86].
Regulation of gut permeability by diet, prebiotics and
probiotics
Since we now know about the clinical implications, inter-
est in understanding the regulation of this barrier is grow-
ing. Two major regulatory factors could be identified,
diet/nutrients/prebiotics, and, secondly, the intestinal
microbiota/probiotics. Both are related to life style, which
suggests that environmental factors might influence the
function of the intestinal barrier and thus gut health [6].
The molecular mechanisms that regulate the epithelial
tight junction and the paracellular pathway in response to
luminal nutrients as D-glucose are less well defined but
have been proposed to involve the cytoskeleton including
myosin light chain phosphorylation [87].
The effect of diet on intestinal permeability is dependent
on individual factors such as the host’s genetic susceptibility,
and also on the intestinal microbiota. For example, the
increased gut permeability during metabolic adaptation to
high fat diet (HFD) is associated to altered gut microbiota
[13]. Dietetic factors that promote increased intestinal per-
meability and subsequent translocation of bacteria resulting
in inflammatory reactions in the liver, the white adipose
tissue, the brain, and other organs trigger metabolic diseases
such as insulin resistance. This pathophysiological cascade is
now accepted to be of major relevance for the development
of metabolic diseases including type II diabetes, cardiovascu-
lar diseases and non-alcoholic fatty liver disease (NAFLD) or
non-alcoholic steatohepatitis (NASH) [88-93]. Therefore it is
tempting to speculate that tools allowing a safe modulation
of the intestinal microbiota such as prebiotic food compo-
nents or probiotic bacteria might be of great interest for
future therapy of intestinal barrier-related diseases.
Vitamins
Vitamin A and its derivatives have been shown to regulate
the growth and differentiation of intestinal cells, whereas
vitamin A deficiency is associated with increased suscepti-
bility to infection in both human and animal models [1].
Table 3 Pathogen interactions with epithelial tight junctions
Bacteria Bacterial factors Mechanism of TJ disruption Host targets References
H. pylori CagA Cdx2-mediated increase in claudin 2 expression PAR1 [64-66]
Urease Phosphorylation of myosin light chain kinase
and occludin internalization
MLCK, ROCK [67]
Unknown Rho kinase (ROCK)-dependent loss of TJ claudin-4 IL-1R1, ROCK [68]
EPEC Map Cdc42-dependent filopodia and pedestal formation Cdc42 [69]
EspM Activation of RhoA and TJ disruption RhoA [70-72]
NleA Inhibition of host cell protein trafficking through
COPII-dependent pathways
COPII [73]





Filopodia formation and alteration of
actomycin ring
Rho GTPase [76]
Clostridium difficile enterotoxin A and B Inactivation of Rho family proteins causing
degradation of filamentous actin
Rho and Cdc [77]
Bacteroides fragilis Enterotoxin or fragilysin Toxin degradation of E- cadherin and alteration
of actomycin ring
E-cadherin [78]
Vibrio cholera HA protease HA induced cleavage of occludin, alteration
of ZO-1 and rearrangement of actin
Occludin [79]
Abbreviations: TJ tight junctions, PAR1 phytochrome rapidly regulated 1 gene, MLCK myosin light chain kinase, ROCK Rho-associated, coiled-coil containing protein
kinase 1, IL-1R1 interleukin 1 receptor, type I, Cdc42 cell division cycle 42, RhoA ras homolog family member A, COPII Rho GTPase, EPEC enteropathogenic Escherichia coli.
Other explanations see text.
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ations within the commensal bacteria, and impairs the intes-
tinal barrier by changing mucin dynamics and expression of
defense molecules such as MUC2 and defensin 6 [94].
Vitamin A deficiency is associated with a decreased small
bowel villus height and a reduced disaccharides activity lead-
ing to more severe intestinal injury in experimental enteritis
[95]. Cross-sectional investigations of children with high
rates of subclinical vitamin A deficiency showed that serum
retinol concentrations are inversely correlated with intes-
tinal permeability [96]. Apart from vitamin A, also vitamin
D seems to play a role for the intestinal barrier. Vitamin D
deficiency, a characteristic of IBD, is correlated with the
severity of disease [97]. Experiments in vitamin D receptor
knockout mice showed that vitamin D deficiency might com-
promise the mucosal barrier, leading to an increased suscepti-
bility to mucosal damage and an increased risk of IBD [98].Short chain fatty acids (SCFA)
These organic acids comprising acetate, propionate, butyr-
ate and valerate are produced by intestinal microbial fer-
mentation of undigested dietary carbohydrates in the colon.
Among them, butyrate plays a particular role for maintain-
ing the intestinal barrier, as shown in IBD, in which deficit
in butyrate causes tight junction lesions and finally im-
paired intestinal permeability [99]. In turn, experiments in
a rat model of DSS-induced colitis showed that treatment
with butyrate leads to a recovery in transepithelial resist-
ance, which was associated with maintenance of tight
junction integrity and inhibition of TNFα release [100].Prebiotics
Apart from the effects of fermentation products of pre-
biotics such as SCFA, prebiotics by itself might have
stabilizing effects on the intestinal barrier. Indeed, prebiotic
galactooligosaccharide (GOS) protects against salmonella
infections and against barrier impairment in experimental
pancreatitis [101,102]. Most recently, the group of Cani and
Delzenne showed that prebiotic fructo-oligosaccharides
(FOS) attenuate experimental hepatic steatosis, possibly
by modulating the intestinal microbiota or the intestinal
barrier function or both [103].Western style diet
A number of animal studies investigated effects of high-fat
diets on the composition of gut microbiota and on intes-
tinal permeability [9,13]. Consistently, energy-rich high-fat
diets enhanced intestinal permeability resulting in meta-
bolic endotoxinemia. The Western style diet, which is
characterized by a high amount of fat and carbohydrates,
induced similar or even more pronounced changes [10].
Moreover, our studies revealed that among dietary sugars
fructose plays a particular role with regard to the intestinal
barrier. Using TLR-4 mutant mice we showed that the
onset of fructose-induced NAFLD is associated with intes-
tinal bacterial overgrowth and increased intestinal perme-
ability, subsequently leading to an endotoxin-dependent
activation of hepatic Kupffer cells [104]. Recently, we could
also show in a mouse-feeding model that chronic consump-
tion of 30% fructose solution for eight weeks was associated
with the loss of the tight junction proteins occludin and
Figure 4 Intestinal barrier dysfunctions. Intestinal permeability
measurements are determined by the marker molecules used for
measurement, since the type of molecules that pass the intestinal
barrier depends on the type of lesion.
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ial endotoxin in the portal vein [105]. Apart from vitamins
and fatty acids, other dietetic factors have been examined
such as plant-derived flavonoids, e.g. quercetin present in
grapes and onions, which increased epithelial resistance and
claudin-4 expression in epithelial cells [106,107].
Probiotics
Several studies report the use of commensal bacteria and
probiotics to promote intestinal barrier integrity in vivo
[108-111] although some studies have been negative or
inconclusive. Many studies report enhancement of the
intestinal barrier in vitro or protection from barrier dis-
ruption by probiotics. For example, the probiotic E.coli
Nissle 1917 (EcN) was shown to prevent barrier disruption
caused by infection of T84 and Caco-2 cells with an
enteropathogenic E. coli strain [112]. The addition of EcN
alone increased expression of ZO-2 protein and redistri-
bution of ZO-2 from the cytosol to cell boundaries
in vitro [112]. EcN also increases claudin-14 expression in
the epithelial TJ and its effect is mediated via TcpC via
PKC-zeta and the MAPK ERK1/2. A similar effect was
observed in intestinal epithelial cells isolated from germ-
free mice treated with EcN [113]. Metabolites secreted by
Bifidobacterium infantis Y1, one of the components of the
probiotic product VSL#3, leads to an increase in expres-
sion of ZO-1 and occludin while reducing expression of
claudin-2 leading to enhanced effects on transepithelial
resistance and altered ion secretion [114]. Another
probiotic strain Lactobacillus plantarum MB452 (from
the VSL3 probiotic) was shown to induce transcription
of occludin and cingulin genes [115].
Enteric pathogens often gain access to the body by
altering the structure and function of tight junctions to
increase permeability of the barrier via the secretion of
proteases, which can cleave tight junction proteins or by al-
tering the cytoskeleton [116]. Inflammatory cytokines such
as TNFα and IFNγ, which are induced during infection and
in IBD, have been shown to increase intestinal permeability
in general, although single inflammatory models yielded
different results [114] while probiotics and commensals can
reverse such inflammatory dysfunctions in human intes-
tinal epithelial cells, e.g. by improving barrier functions or
by inhibition of pathogen adherence [115,117-120]. Also
synergistic effects between sIgA and probiotics have been
described [121].
Importantly, one study has shown that L. plantarum
can regulate human epithelial TJ proteins in vivo and
to confer protective effects against chemically induced
disruption of the epithelial barrier in an in vitro model
[122]. Administration of L. plantarum into the duodenum
of healthy human volunteers was shown to significantly
increase ZO-1 and occludin in the vicinity of TJ structures
[122]. These results suggest that administration of L.plantarum can enhance the stability of TJ complexes in
humans and may attenuate their disruption by cytokines,
toxins and pathogens. Apart from L. plantarum, other
probiotic Lactobacillus strains seem to have protective
effects on the intestinal barrier using different in vitro
settings or mouse models of disease, namely L. salivarius
strains UCC118 and CCUG38008, L. rhamnosus GG,
Lactobacillus casei strain DN-114 001, and L. casei strain
Shirota [123-127]. Also the probiotic E. coli Nissle 1917
up-regulates tight junction proteins such as claudin 14
expression and other components of the intestinal barrier
[112,113,128].
In summary, imbalances in the composition of bacterial
community in the intestine can lead to transient intestinal
dysfunctions, barrier modulation, and chronic disease
states such as IBD. Understanding how this ecosystem is
regulated, e.g. by diet and other exogenous factors, and
how to manipulate it is thus essential for disease preven-
tion and therapy.
Measurement of intestinal permeability
Intestinal permeability and integrity can be measured in
many ways. The techniques used for permeability and
integrity assessment vary depending on the setting (in vitro
versus in vivo measurements), the species (human or
animal models), the marker molecules used for assessment
(ions, carbohydrates of different sizes, macromolecules and
antigens, bacterial products and bacteria), and the com-
partments used for measurement of the marker molecules
(peripheral blood, portal vein blood, urine). If one focuses
just on the epithelial barrier, the flux of molecules is very
much dependent on the type of molecules and the type of
defects, as illustrated in Figure 4. To measure such dysfunc-
tions, the Ussing chamber is widely used, both for human
and animal studies. This ex vivo approach to measure intes-
tinal permeability requires intestinal tissue specimens, either
biopsies or surgical specimens.
In vivo assessment of intestinal barrier function and per-
meability in humans is currently possible by using intestinal
permeability assays, and by the assessment of biomarkers
of epithelial integrity such as soluble adhesion molecules,
other biomarkers of immunity or inflammation, or bacterial
Bischoff et al. BMC Gastroenterology 2014, 14:189 Page 9 of 25
http://www.biomedcentral.com/1471-230X/14/189markers like circulating endotoxin (Tables 4 and 5). In
addition, histological approaches and scanning electron
microscopy analyses have been used in experimental
settings. The most relevant methods for assessment of in-
testinal barrier function and permeability in clinical set-
tings are described in more detail in this chapter.
The Ussing chamber
The Ussing chamber allows the measurement of short-
circuit current as an indicator of active ion transport taking
place across the intestinal epithelium. Basically, the chamber
consists of two halves that are mounted together containing
the tissue specimen with the apical side isolated from the
basolateral side. The two half chambers are filled with equal
amounts of Ringer solution (Figure 5). The active ion trans-
port produces a potential difference across the epithelium
(VEP). The voltage difference generated is measured using
two voltage electrodes that are placed as near as possible
to the tissue/epithelium. The spontaneous voltage is can-
celled out by injecting a counter current using another two
current electrodes that are placed far away from the epithe-
lium. This current externally injected is called short-circuit
current (Isc) and is the exact measure of net ion transport
taking place across the epithelium. The transport of ions
through the epithelium, in particular the secretion of chlor-
ide, plays an important role in the gut, and is paralleled by
water transport [15,129].
Recent studies showed that luminal factors such as nutri-
ents, bacteria, and bacterial products including probioticsTable 4 Means for the assessment of intestinal permeability (
Means Hu An Test molecules
Ex vivo
Ussing chamber x x H2O, ions, sugars etc.,
In vivo – permeability assays
Lactulose/mannitol x x oligosaccharides of different MW
Sucralose x (x) sucralose(comb.)*
Sucrose x (x) sucrose(comb.)*
PEG4000/400 x (x) polyethylene glycols
51Cr-EDTA x x 51Cr-EDTA
In vivo – bacteria-related
LAL assay x x endotoxin (LPS)
EndoCAb x x anti-LPS antibodies
D-lactate x x bacterial lactate
Butyrate production x x BPB (PCR)
Hemolysin test x x pathogens (cell culture)
Inner colon mucus x x quantification of bacteria
Liver steatosis x x fat content in the liver
Breath tests x x fat content in the liver
Abbreviations: Hu suitable for the human system, An suitable for animal models, 51C
circulating endotoxin core antibodies, GC gas chromatography, LAL limulus amebocyte
MS mass spectroscopy, PEG polyethylene glycols, US ultrasound. *in combination withcan restore intestinal permeability previously impaired by
infections or chronic inflammation, as assessed in the
Ussing chamber [16,130,131]. In addition, also glutamine is
an important luminal component thought to preserve
intestinal barrier function, although the molecular mechan-
ism beyond its role as a metabolic fuel is not yet established
[132]. Most importantly, malnutrition is associated with
increased intestinal permeability, as shown in liver cirrhosis
patients, suggesting that nutrients are needed to maintain
normal barrier function in the intestine [133]. The Ussing
chamber technique is well established since many years and
has been successfully used for both human and animal
studies. Limitations of Ussing chamber measurements are
the invasiveness because of the need for fresh intestinal tis-
sue, and the lack of correlations between Ussing chamber
data and other permeability assays raising the question of
which aspects of the intestinal barrier can be assessed by this
approach.
Permeability assays
Permeability assays usually use oligosaccharides of large
size, e.g. lactulose or high MW-PEGs of 1500 or 4000 kD,
and sugars of small size, e.g. mannitol, L-rhamnose, or
low MW-PEG of 400 kD, or other indigestible probes
such as 51Cr-EDTA that are administered orally. The
large size molecule is thought to cross the paracellular
intestinal pathway only if the intestinal barrier function is
compromised. In case of barrier function loss such probes
cross the intestinal barrier, appear into the circulation andfunctional tests, bacteria-related tests)
Test site Material needed Disadvantages
site specific biopsies invasive
small intestine urine time consuming
colon urine time consuming
stomach urine time consuming
whole intestine urine time consuming
whole intestine urine radio-activity
whole intestine plasma assay limitation
whole intestine serum only in acute phase
whole intestine plasma low specificity
colon feces special labs, limited data
colon feces special labs, limited data
colon biopsies invasive,limited standardization
whole intestine MRT, US expensive unspecific
whole intestine GC/MS unclear specificity
r-EDTA chromium labeled EDTA, BPB butyrate-producing bacteria, EndoCAb
lysate assay, LPS lipopolysaccharide, MRT magnetic resonance tomography,
Lactulose/mannitol test.
Table 5 Means for the assessment of intestinal permeability (biomarkers, histology)
Means Hu An Test molecules Test site Material needed Disadvantages
In vivo – biomarkers of epithelial cell damage
Citrulline x x endogenous ep product small intestine plasma
FABP x x endogenous ep marker site- specific plasma only in acute phase?
αGST x x endogenous ep enzyme n.a. plasma, urine only in acute phase?
Claudin-3 x x ep tight junction protein n.a. urine limited data
In vivo – other biomarkers
Fecal calprotectin x (x) neutrophil release product colon feces unspecific marker of gut inflammation
α1-anti- trypsin test x (x) endogenous amino acid small intestine feces/ serum unclear specificity
sIgA x x IgA (ELISA) whole intestine serum low specificity
In vivo – histological approaches
Tight junction expression x x RNA (qPCR), Western blot site- specific biopsies invasive
Goblet cell analysis x x histology site- specific biopsies invasive
Shedding of epithelium x x histology site- specific biopsies invasive
Paneth cell loss** x x histology site- specific biopsies invasive
Defensins RNA (qPCR), Western blot site- specific biopsies invasive
Mucus analysis*** histology/ staining site- specific biopsies invasive
Abbreviations: αGST α-glutathione S-transferase, ep epithelial, FABP fatty acid binding protein, n.a. not applicable, qPCR qunatitative PCR, see also Abbreviations in
Table 4. **Ref. Nr. 226; ***Ref. Nr. 227.
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size molecule is thought to traverse the intestinal barrier
freely, independent of barrier function loss, and is affected
in the same way as the large molecular probe by the pre-
and postmucosal confounders like as gastric dilution,
gastrointestinal motility, bacterial degradation, and renal
function. Therefore, the ratio of the urinary concentration
of both molecules measured after 5–6 h would more accur-
ately reflect the paracellular passage across the intestinal
barrier than isolated measurement of urinary oligosaccha-
rides. The “active” test results depend on the test probe size,
the way of absorption (passive or active transport in the in-
testine), the site and velocity of absorption, and the kineticsFigure 5 The Ussing chamber. Upper left: Ussing chamber
equipment. Upper right: Mounting a tissue specimen in a chamber
for measurement. Lower panel: schematic view of an Ussing
chamber setting. For details see text.of distribution into different body compartments. Alterna-
tively to this “active” assessment of the barrier, “passive”
assessment of the barrier is possible by the quantification of
luminal compounds such as endotoxins and bacterial
fermentation in plasma as markers for barrier function in-
tegrity. The advantage of this approach is that no time-
consuming urine collection is needed. On the other hand,
the substances are not always easily measured because of
technical limitations (e.g. endotoxin assays) or hepatic
metabolism [17,134].
Laboratory analysis of urine samples is usually performed
using high pressure liquid chromatography (HPLC) or li-
quid chromatography in combination with mass spectrom-
etry (LC/MS). Since some of the saccharides, as lactulose,
can cause increased intestinal motility, the administered
dose should be kept as low as possible. Permeability assays
are usually useful only for assessing small intestinal perme-
ability, since lactulose is degraded by bacteria in the large
intestine. To evaluate whole intestinal permeability, non-
degradable probes such as sucralose or erythritol, which
remain unaffected by bacteria in the colon, are added to
classical DST, resulting in the so-called triple sugar test.
The lactulose excretion over 24 h (likely to represent only
small intestinal permeability), subtracted from 24-h sucral-
ose excretion, is considered to give an isolated measure of
colonic permeability [134]. Other studies focused on meas-
urement of gastroduodenal permeability, have used sucrose
or glucose as test substances. Sucrose is rapidly degraded
by sucrase, an enzyme secreted in large amounts by mature
enterocytes in the duodenum. Therefore, enhanced plasma
or urinary levels of sucrose are thought to reflect only
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Glucose is even independent of sucrose digestion. Most
recently, both approaches have been combined to assess in-
testinal permeability at different sites. The "multi sugar test"
is based on administration of sucrose, lactulose, sucralose,
erythritol, and rhamnose simultaneously in order to assess
gastro-duodenal, small intestinal and large intestinal perme-
ability in humans [136].
Increased permeability for saccharides has been reported
in patients with CD [137,138], celiac disease [139], adverse
reaction to food [140,141], and in critically ill patients or
patients undergoing major surgery [142,143]. In contrast to
lactulose and mannitol, PEGs have the advantage of being
inert and can therefore be used to measure both small and
large intestinal permeability. They have been used success-
fully to assess permeability changes in patients with irritable
bowel syndrome [144], pancreatitis [145], liver cirrhosis
[146], and intestinal ischemia reperfusion injury [147].
Some studies have reported increased colorectal permeabil-
ity for 51Cr-EDTA in patients with IBD [148]. However,
the tests have never gained a place in everyday practice for
diagnosis and follow up of such patients groups, mainly
because the test is impractical in use and detection
methods are complex and not widely available.
Some studies, however, have shown that such permeabil-
ity assays in intensive care patients have pitfalls. Firstly,
decreased motility and altered clearance of the different
sugars as a result of renal dysfunction is a complicating
factor in these patients. Secondly, the use of mannitol
appeared to be unsuitable in patients receiving red blood
cell transfusion, since mannitol is used in the storage
solution of bank blood [17].
Bacteria-related markers
LPS measurement Despite well-known technical limita-
tions of the assay, resulting from the low levels detectable
in peripheral blood, several studies have successfully used
LPS assays to show endotoxemia, mostly in patients with
sepsis [149]. Enhanced levels of LPS were found also in
patients with obesity and metabolic syndrome [150,151],
which might indicate bacterial translocation from the
gut lumen to the circulation as a consequence of intes-
tinal barrier function failure. While LPS can be quite
easily measured in portal vein blood in animals, it re-
mains a challenge to measure LPS in peripheral blood in
humans and it requires careful standardization of the
measurement.
Circulating endotoxin core antibodies (EndoCAb)
Alternatively to the measurement of endotoxin, which
yields best results if measured in portal vein plasma, meas-
urement of circulating EndoCAb allowing the quantifica-
tion of immunoglobulins (IgG, IgM and IgA) against the
inner core of endotoxin have been proposed for the acutephase of intestinal barrier damage. This inner core con-
sists of a hydrophobic part, lipid A, which is attached to a
core oligosaccharide. Lipid A is highly conserved across
the whole range of Gram-negative microbiota. Moreover,
it is this part that is considered responsible for endotoxin
toxicity. Several studies showed decreased EndoCAb levels
postoperatively, accounting for the degree of exposure to
endotoxin [152,153]. Thus, consumption of these circulat-
ing immunoglobulins following translocation of gut-
derived endotoxins can be used to acquire indirect
information on the intestinal epithelial barrier function.
The approach is so far limited by the fact that it has been
performed successfully only in postoperative patients but
not in patients with chronic diseases.
Plasma D-lactate level have been originally proposed as
a marker for diagnosis of bacterial infections, since D-lactate
is a fermentation product produced by many bacteria includ-
ing those present in the human gastrointestinal tract. Low
circulating levels of D-lactate are found in healthy individ-
uals, but in case of intestinal barrier function loss, these
levels will rise as a consequence of increased translocation
across the intestinal mucosa. Various studies proposed a
relationship between plasma D-lactate and intestinal perme-
ability, e.g. in patients undergoing open aortic surgery and is-
chemic colonic injury. However, results should however
be interpreted cautiously where there is bacterial over-
growth since the augmented presence of bacteria could re-
sult in increased fermentation of undigested carbohydrates
to D-lactate. Therefore, the usefulness of plasma D-lactate
as marker for colonic barrier function in man is a subject
for future research [17].
Fecal butyrate concentrations Generation of SCFA
such as butyrate depends on prebiotic and other dietetic
factors as well as on the composition and activity oft he
intestinal microbiota. It has been shown that butyrate
decreases bacterial translocation in cells models [154]
and modifies the expression of the tight junction pro-
teins claudin-1 and claudin-2 in favor of a barrier preser-
vation [99,155]. Therefore, butyrate deficiency can be
taken as an indirect indicator of impaired intestinal bar-
rier function.
Bacteria-derived hemolysin is a pro-inflammatory toxin
that can impair the intestinal barrier. Conditions leading
to enhanced hemolysin concentrations in the intestine
will enhance intestinal permeability [156]. However,
butyrate and hemolysin assays are poorly established for
permeability assessment so far.
Assessment of fatty liver disease Translocation of bac-
terial or bacterial products such as LPS from the intestine to
the liver has been proposed as trigger for liver inflammation
and fatty liver disease [151]. We could show that LPS trans-
location indeed induces hepatic steatosis in mice suggesting
Bischoff et al. BMC Gastroenterology 2014, 14:189 Page 12 of 25
http://www.biomedcentral.com/1471-230X/14/189that enhanced intestinal permeability is associated with fatty
liver disease assessed by histological examination, magnetic
resonance tomography or sonography [104]. Alternatively,
fatty liver disease can be assessed by a combination of three
volatile bacterial compounds exhaled by a breath test and
analyzed by gas chromatography–mass spectrometry [157].
It has to be considered that LPS is likely not the only mecha-
nisms that might cause fatty liver disease, limiting the speci-
ficity of this approach.
Analysis of intestinal mucus for bacterial content
Most recently, it has been shown that under conditions
characterized by an impaired intestinal barrier, luminal bac-
teria enter the inner colon mucus normally impenetrable
for the commensals [28]. Therefore, measurement of bac-
teria in the inner colon mucus of biopsies could serve as a
novel marker of intestinal barrier function and permeability.
However, a better standardization of this analysis is wanted
to establish it as a novel permeability assay.
The bacteria-related markers are clearly less estab-
lished as markers for intestinal permeability in humans
compared to the classical permeability assays; however,
the fact that they likely reflect different characteristics of
the intestinal barrier, is of great interest and might
become of more relevance in future.
Biomarkers of epithelial cell integrity
Plasma levels of citrulline, an amino acid not incorporated
into proteins, but produced by small intestinal enterocytes
from glutamine have been proposed as a marker of func-
tional enterocyte mass. Loss of small bowel epithelial cell
mass results in impaired intestinal permeability and in de-
clined circulating levels of citrulline, as is shown in haemo-
poietic stem cell transplant recipients suffering from severe
oral and gastrointestinal mucositis following intensive mye-
loablative therapy [158]. More recently, citrulline was estab-
lished as a valuable marker for chemotherapy-induced
mucosal barrier injury in pediatric patients [159]. Most inter-
estingly, sensitivity and specificity seem to be better for the
citrulline assay compared with sugar permeability tests [160].
Fatty acid binding proteins (FABP) are small (14–15 kDa)
cytosolic water-soluble proteins, present in mature entero-
cytes of the small and large intestine. Their function is the
transport of fatty acids from the apical membrane of the
enterocyte to the endoplasmic reticulum where biosyn-
thesis of complex lipids occurs. Three types of FABP are
present in the gut; intestinal FABP (I-FABP) found pre-
dominantly in the jejunum – less in the colon, liver FABP
(L-FABP) found in liver, kidney and intestine, and ileal bile
acid binding protein (I-BABP) exclusively present in the
ileum. FABP can be measured sensitively in both plasma
and urine using an enzyme-linked immunosorbent assay
(ELISA). Basal levels of FABP have been reported to
reflect the physiological turnover rate of enterocytes,whereas elevated levels indicate intestinal epithelial
cell damage. Elevated circulating or urinary FABP levels
were reported in patients with intestinal ischemia, systemic
inflammatory response syndrome (SIRS) and necrotizing
enterocolitis [161-163]. Moreover, FABPs have been estab-
lished as markers of the intestinal barrier function with
prognostic relevance in patients with liver transplantation
[164], and for disease activity in celiac disease [165,166].
Since FABP are differentially expressed along the intestinal
tract, measurement of specific FABP could be a promising
tool to provide information on disease localization [17].
However, data are limited for changes in chronic diseases
such as IBD or metabolic disorders.
Glutathione S-transferases (GSTs) are involved in cell
protection, antioxidation and detoxification of toxic and
foreign compounds within the cell by conjugating them to
glutathione. The GST family consists of four subgroups
displaying tissue variation; αGST, μGST, πGST and θGST.
Whilst μGST, πGST and θGST are present in cells of vari-
ous organs, αGST is predominantly present in liver, kid-
ney and intestine and has been proposed as a potential
marker for, amongst others, intestinal epithelial cell dam-
age [17]. Several studies reported that mesenteric ischemia
could reliably be predicted by plasma αGST levels in patients
suspected for acute mesenteric ischemia [167,168]. However,
increased plasma or urine levels of αGST can indicate
intestinal damage as well as liver and kidney damage,
because αGST is expressed in epithelial cells of all these
organs. Therefore, this test might be useful for assessment
of intestinal damage when isolated intestinal damage is
suspected.
Tight junction (TJ) status can be assessed as a marker
for paracellular barrier integrity loss. In particular, clau-
dins are transmembrane epithelial proteins being mainly
responsible for intestinal barrier function. The group of
Schulzke an co-workers showed a disturbance of the
barrier function which was accompanied by a down-
regulation of claudin-1, 3, 5, 7 and 8, and an up-
regulation of claudin-2, a pore-forming claudin, together
with a re-distribution of claudin-5 and −8 off the tight
junction domain of the enterocytes in intestinal biopsies
of patients with CD [23]. Recent studies showed a strong
relationship between intestinal tight junction loss and urin-
ary claudin-3 levels in both a rat hemorrhagic shock model
and in patients suffering from IBD or necrotizing entero-
colitis, or undergoing major surgery, thereby suggesting
that measurement of urinary claudin-3 can be used to some
extent as non-invasive marker for intestinal tight junction
loss [17].
Biomarkers of intestinal inflammation and intestinal
immunity
Fecal calprotectin A broad range of pathologies can
lead to intestinal inflammation such as neoplasia, IBD,
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hypoperfusion, and selected drugs like non-steroidal
anti-inflammatory drugs. Generally, defects or increased
permeability of the mucosal barrier will cause intestinal
inflammation in response to the enormous number of
bacteria present in the bowel. Recruitment of leukocytes
into the intestinal wall is important in the pathogenesis
of intestinal inflammation. Activated neutrophils infil-
trate the mucosa and their products can be detected in
feces. Numerous neutrophil derived proteins present in
stool have been studied, including calprotectin, lactofer-
rin, and elastase. The most promising marker is calpro-
tectin, because of its remarkable resistance to proteolytic
degradation and its stability in stool kept at room
temperature for at least seven days [169]. It constitutes
about 60% of the soluble proteins in human neutrophilic
cytosol and is also found in monocytes, macrophages,
and ileal tissue eosinophils. It is released during cell acti-
vation or cell death and has antiproliferative, antimicro-
bial, and immunomodulating functions [169,170]. Fecal
calprotectin is nowadays used in clinical practice to
evaluate disease activity in the follow-up of patients
treated for active IBD and can be easily performed [171].
Apart from calprotectin, other markers of intestinal
immunity such as secretory IgA [172] and defensins have
been proposed as markers of intestinal permeability.
Whereas secretory IgA has been examined in patients
with celiac disease, defensins have been analyzed mostly
in patients with IBD [173]. More recently, fecal human
β-defensin-2 has been suggested as a marker for intes-
tinal permeability in neonates [174].
Since many years, the macromolecules ovalbumin,
which is measured in the serum, and FITC-labeled dex-
tran that is uptaken in the ileum and transported fur-
ther to the mesenteric lymph nodes, have been used as
markers for small intestinal permeability. Likely, suchFigure 6 Tight junctions in the intestine. This figure is based on previou
a tissue section perpendicular to the cell surface of the epithelium (A). The
plotted as a function of cell location using the peak fluorescence signal fro
Administration of live L. plantarum to humans significantly increased the fl
sections indicated *).high-MW markers indicate different qualities of the in-
testinal barrier than oligosaccharides, but direct com-
parisons of the different tracers are lacking. On the
other hand, their value remains unclear, because in vivo
data in humans are scare. Most experiments using ov-
albumin or FITC-labeled dextran have been made ei-
ther in rodents or in Ussing chambers.
Histological approaches Altered tight junction com-
position can lead to changes in epithelial permeability.
Changes in tight junction proteins can be quantified in
histological tissue samples by confocal analysis of uni-
form Z sections perpendicular to the cell surface of the
epithelium (Figure 6). Recently this technique was used
to measure changes in tight junction staining in human
duodenal tissue and in vitro epithelial cell monolayers
following administration of a probiotic [122].
Intestinal permeability – a new target in health and
disease?
A number of different diseases comprising intestinal and
extraintestinal diseases have been found to be associated
with alterations in the intestinal barrier and increased
permeability, respectively (Table 6). Among these, IBD
and IBS, critical illness, and – more recently – obesity
and metabolic diseases have experienced increasing at-
tention and therefore they will be discuss in this chapter
in more detail. Other diseases such as celiac disease
need to be mentioned as an example of a disease related
to intestinal permeability [175,176]. The realization that
the barrier is so important, raises the question of what
can disrupt the barrier. Even though no final conclusions
can be drawn, it became more and more evident that be-
sides nutrients acting as down-regulators of tight junc-
tions or as histone deacetylase (HDAC) inhibitors, also
viral infections, toxins, hypoperfusion of the gut play asly published data [115] and shows fluorescent staining of occludin in
fluorescence intensities of 3 different uniform areas per section were
m the tight junction region to align each intensity profile (B).
uorescent staining of occludin in the tight junction (P < 0.05 for
Table 6 Diseases related to intestinal permeability
Intestinal Extraintestinal
Gastric ulcers Allergies
Infectious diarrhea Infections (e.g. respiratory)
Irritable bowel syndrome;
functional GI diseases
Acute inflammation (sepsis, SIRS, MOF)
Inflammatory bowel
disease, Celiac disease




(NASH, diabetes type I and II, CVD)
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ing/country site or urban environment), exercise and drug
usage seem to play an important role as well, and they
offer new approaches for improving gut barrier function
[4,6].Role of intestinal permeability and probiotics in IBD
Intestinal barrier dysfunction is a main feature of CD
and UC [1,16,138]. Already 20 years ago it was found
that increased intestinal permeability precedes clinical
manifestations of CD, but is insufficient to cause disease
suggesting other factors being involved [137,177]. Leak
flux diarrhea and a facilitated uptake of noxious antigens
are the two consequences resulting from an impaired
epithelial barrier. Barrier perturbations in IBD comprise
alterations in epithelial TJ, i.e. a reduced number of
horizontal TJ strands and an altered TJ protein expres-
sion and subcellular distribution. Recently, prion protein,
a ubiquitous cellular glycoprotein being involved in cell
adhesion, was found to be dislocated in IBD supporting
the concept that disrupted barrier function contributes
to this disorder [178]. Moreover, increased incidence of
apoptotic events, epithelial cell shedding, as well as ero-
sions and ulcerations can add to that leakiness [179].Table 7 Possible causes of impairment of the intestinal
barrier
Nutritional factors Tight junction downregulation
Histone deacetylase (HDAC) inhibitors
ENS modulators
Infections & toxins Viral intestinal infections
Environmental toxins
Toxic food
“Hygiene hypothesis” Sterile environment
Lack of farming
“Lifestyle hypothesis” Impaired function and diversity
of the intestinal microbiota
Endogenous factors Hypoperfusion of the intestine
Chronic inflammation/autoimmunityThese barrier defects are attributed to enhanced ac-
tivity of pro-inflammatory cytokines like TNFα, INFγ,
IL-1β and IL-13, which are highly expressed in the
chronically inflamed intestine. They can be detected
in vivo in humans by fluorescein leakage analysis and
confocal laser endomicroscopy. Crucially, increased cell
shedding causing microerosions and barrier loss as
assessed by confocal laser endomicroscopy predicts re-
lapse in CD over a 12 month period [35].
Although the etiology of IBD is far from being clear,
chronic inflammation is believed to result from an inad-
equate immune response as a consequence of genetic pre-
disposition as well as changes in, and altered responses to
the intestinal microbiota. On the other hand, an insuffi-
cient mucosal response to bacterial stimuli results in an
insufficient immune response towards intestinal patho-
gens. The detailed characterization of barrier defects offers
the opportunity to consider and test therapeutic interven-
tions. Beside cytokine antagonists, different plant com-
pounds and probiotics have been shown to stabilize the
barrier function by affecting TJ protein expression and
distribution [16]. Among the plant compounds, Kiwifruit
extracts as well as different polyphenols have been found
to exert anti-inflammatory effects in models of IBD and in
human disease [180-182].
The first reports on beneficial effects of probiotics in
IBD was on E.coli Nissle 1917 supporting maintenance
of remission in patients with UC [183,184]. The next im-
portant finding was that the probiotic mixture VSL#3 re-
duces and protects against pouchitis in patients with UC
[185,186]. Since then, more than 80 RCT have been pub-
lished showing beneficial effects of probiotics in adults
and children with UC, but hardly in CD. For example,
VSL#3 seems to be effective not only in pouchitis, but
also in mild to moderate UC not responding to conven-
tional therapy [187]. More recently, the positive findings
could be extended to children with active UC, who im-
proved after treatment with the probiotic L.reuteri or
VSL#3 [188,189].
The mechanisms of probiotic effects in IBD is unclear at
present, but might involve direct anti-inflammatory ef-
fects, e.g. by modulating TLR signaling , or indirect effects
such as improvement of the intestinal barrier [190,191].
Role of intestinal permeability and probiotics in IBS
Intestinal barrier dysfunction has been found to play a
pathogenic role not only in IBD, but also in IBS [1].
Most importantly, there is evidence now that increased
intestinal permeability is related to low-grade inflam-
mation, visceral hypersensitivity and pain in IBS [192].
In diarrhea-predominant IBS (IBS-D), electron microscopy
studies showed cytoskeleton condensation and enlarged
intercellular spaces between epithelial cells, providing the
morphological basis for increased intestinal permeability in
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with mast cell activation and symptoms including diarrhea
and pain severity [193]. These data confirm and extent
earlier observations derived from Ussing chamber experi-
ments showing increased paracellular permeability in colon
tissue of IBS patients [194]. The primary cause of the de-
scribed morpho-functional changes in intestinal permeabil-
ity remains to be determined. Potential factors include
intestinal food allergies, genetic and epigenetic factors,
changes in intestinal microbiota. Regardless the cause, mu-
cosal barrier defects determine an increased flow of anti-
genic substances that challenge the mucosal immune
system. Interestingly, several studies have provided evi-
dence of low-grade immune activation and release of in-
flammatory molecules in IBS which in turn maintain the
increase in intestinal permeability [195]. Possibly, the loss
of particular TJ proteins such as occludin is a result of in-
creased proteasome-mediated degradation observed in IBS
triggered by low-grade inflammation and resulting in in-
creased intestinal permeability [196]. Such data point out
the importance of the intestinal barrier in the pathophysi-
ology of IBS and provide evidence for the organic nature of
such so-called functional gastrointestinal disorders.
Food, microbiota and bile acids have been discussed as
possible inducers of low-grade inflammation and impaired
permeability in IBS. In a subgroup of patients, IBS is prob-
ably related to food allergy [197,198]. Apart from external
inducers, endogenous triggers such as mast cell-derived
histamine, proteases and eicosanoids can increase intes-
tinal permeability, either directly or via stimulation of
neurons of the enteric nervous system [194,199,200].
Serotonin, another biogenic amine besides histamine, pro-
duced by enterochromaffin cells in the gut, is another en-
dogenous trigger of pain, inflammation and increased
permeability in IBS [201]. Consequently, LX1031, an oral
inhibitor of tryptophan hydroxylase, the key enzyme for
mucosal serotonin synthesis has been successful for treat-
ment of patients with non-constipating IBS [202].
In conclusion, there is now substantial evidence that in-
creased intestinal permeability is associated with immune
activation and symptoms like pain and diarrhea in IBS.
Such knowledge paves the way for the identification of
new disease biomarkers and novel therapeutic targets in
IBS. Apart from mast cell stabilizers [203] and serotonin
antagonists [202], also dietetic approaches [204] and pro-
biotics have been found to be effective to some extent.
The value of probiotics for treatment in IBS was debated
for long time; however, several recent systematic reviews,
guidelines and meta-analyses confirmed, despite all gaps
and methodological limitations, that selected probiotics
are effective in selected subpopulations of patients with
IBS [205-209]. In particular, bloating and distension, for
with other therapeutic approaches are limited, may im-
prove by probiotic treatment [210,211]. Most interestingly,some of the probiotic trials demonstrated that the effects
are correlated with an improvement of the intestinal per-
meability [212].
Role of intestinal permeability and probiotics in obesity and
fatty liver disease
The new concepts on the pathophysiology of obesity and
associated metabolic diseases such as NAFLD and NASH,
type 2 diabetes mellitus or cardiovascular diseases, stating
that such pathologies are related to the intestinal barrier
and the intestinal microbiota, derived predominantly from
mouse studies. It could be clearly shown that metabolic
diseases are linked to increased intestinal permeability and
translocation of bacteria or bacterial products like endo-
toxin from the intestine to the liver and to other tissues
[96,144,213,214]. Moreover, it became clear that the
microbiota of obese [215,216] and diabetic [217] individ-
uals differs from that of the healthy, lean population. In
the meantime, evidence is growing suggesting that these
alterations are of functional relevance.
The altered microbiota in obesity and metabolic dis-
eases contributes to an enhanced harvest of energy from
nutrients. In particular, energy harvest from food carbo-
hydrates depends on the microbiota, because specific
bacteria found to be increased in obese individuals pro-
vide enzymes not expressed by host cells and allowing
the digestion of otherwise more or less indigestible car-
bohydrates [218-220]. In type 2 diabetes, the microbiota
looses its capacity to generate SCFA from prebiotics
[217], which might be a genuine defect or an adaptation
to low fiber intake, which has been revealed by several
epidemiologic studies [221,222].
The altered intestinal barrier and the subsequent trans-
location of small amounts of bacteria or bacterial products
is now regarded as one important mechanism causing the
low-grade inflammation characteristic for metabolic dis-
eases possibly linked to the subsequent infiltration of or-
gans such as liver, muscle and heart muscle with fat
[223-226]. Western style diet rich in fat and sugars alters
the intestinal barrier in a way resulting in enhanced per-
meability and elevated endotoxin levels in the portal vein
[104,150,227].
The result of such alterations is enhanced infiltration of
tissues with bacteria and bacterial products and subse-
quent tissue inflammation and fat accumulation, which
can be observed first in the liver and later on in other tis-
sues such as muscle or heart muscle [150,219,228]. Also
in peripheral blood and in adipose tissue bacteria or bac-
terial products can be observed following feeding with
energy-rich Western style diet, an observation that might
enable to define new bacterial biomarkers of intestinal
barrier dysfunction in metabolic diseases [89,214]. How-
ever, the two alterations, barrier dysfunction and micro-
biota alteration, are not necessarily linked, but can occur
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cept on the pathophysiology of obesity and metabolic dis-
eases that might offer new therapeutic strategies both at
the level of diets and of drugs (Figure 7).
Considering these mechanisms it is tempting to specu-
late that probiotics and prebiotics might have beneficial ef-
fects in chronic metabolic disorders. First data derived
from experimental studies in mice or from preliminary,
human pilot studies indeed point in this direction. For ex-
ample, possible effects of probiotic bacteria or particular
diets on the gut barrier can be studied using organ culture
models [230] or feeding models [13,231]. In humans, over-
feeding alters the bacterial composition of the commensal
microbiota in healthy individuals in a way that results in
increased energy harvest from food [232]. The compos-
ition of the commensal microbiota might allow the predic-
tion of weight gain in human individuals at risk like
pregnant women [233]. In addition, administration of se-
lected prebiotics or probiotics can improve metabolic al-
terations in animal models of metabolic liver disease
[103,127] and in obese human individuals [234,235]. Such
data suggest that new therapeutic concepts could be de-
veloped in the future to support treatment or prevention
of obesity and associated diseases.Figure 7 Current concepts on the pathophysiology of obesity and meRole of intestinal permeability and probiotics in the
critically ill patient
Not only chronic diseases such as IBD, IBS and metabolic
diseases, but also acute intestinal failure and gram-
negative sepsis typically observed in the critically ill pa-
tient are associated with an impaired intestinal barrier and
marked enhancement of intestinal permeability. For that
reason, gram-negative sepsis and subsequent MOF is a
common cause of death in the intensive care unit (ICU)
[236]. Such complications are seen in patients undergoing
major abdominal surgery, but also in trauma patients,
burn patients and other ICU patients [237-239].
Hypo-perfusion of the intestinal tract is regarded as
the culprit of such complications. Therefore, such events
occur also in patients suffering from acute CVD, acute
intestinal ischemia of any cause, and acute enterocyte
toxicity, e.g. in the course of chemotherapy [240,241].
Also under physiological conditions, a hypo-perfusion of
the gut can happen resulting in gut dysfunction, e.g. in
the course of exercise [242]. This can be assessed by gas-
tric tonometry and by using appropriate biomarkers of
enterocyte damage such as intestinal fatty acid binding
protein (I-FABP) and ileal bile acid binding protein
(I-BABP). In particular, I-FABP, a cytosolic protein intabolic diseases related to the gut. For details see text.
Table 8 Factors proposed to support the gut barrier
Dietetic
approach
Avoidance of high amounts of sugar and fat








Probiotic cocktails (multispecies concept)
Synbiotics (combination of probiotics and prebiotics)
Drugs/others Short-chain fatty acids (SCFA)
Metformin
Quercetin and other flavonoids
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and plasma, has been confirmed as valuable marker for
the early diagnosis of intestinal ischemia [243]. Splanchnic
hypo-perfusion can be confirmed in healthy men already
after cycling for 60 minutes at 70% of maximum workload
capacity. A 15 min ischemia causes the appearance of
small subepithelial spaces thought to be morphological
correlates of an impaired gut barrier [244].
Multiple consequences of enteral ischemia have to be
anticipated including mucus barrier loss, bacterial trans-
location, and enhanced Paneth cell apoptosis causing
breakdown of the defensing shield in the intestine
[245,246]. Fortunately, such alterations are rapidly coun-
teracted, e.g. by increased goblet cell secretory activity in
the colon [246]. Even the structural defects such as the
subepithelial spaces are quickly restored by lamina pro-
pria retraction and zipper-like constriction of the epithe-
lium [247]. Such repair mechanisms have been identified
in both rodents and man [248].
The classical treatment of loss of barrier functions in
the ICU patient is usage of antibiotics directed against
gram-negative bacteria and improvement of intestinal
perfusion by catecholamines and volume. If pre- or pro-
biotics can support prevention or treatment of sepsis
and MOF is unclear at present. Some studies suggested
a beneficial effect of selected probiotics and synbiotics
on sepsis complications in patients with major abdom-
inal surgery and in immunocompromised patients who
underwent liver transplantation; however, the trials were
rather small and limited in number [249-251]. Other
studies performed in patients with severe acute pancrea-
titis yielded conflicting results. Whereas a few initial
studies suggested beneficial effects by treatment with
synbiotics [252,253], one trial reported increased mortal-
ity in the verum group [254]. Although this report hat
several methodological limitations, the results underline
that otherwise harmless probiotics have to be selected
and assessed very carefully in severely ill patients similar
to pharmaceutical evaluations. Provided that caution is
considered, clinical trials are warranted to support the
potential use of probiotics in ICU, namely for prevention
of antibiotic-associated and Clostridium difficile-associ-
ated diarrhea, ventilator-associated pneumonia and sep-
sis [255]. A recent meta-analysis drew the conclusion
that the administration of probiotics does not signifi-
cantly reduce ICU or hospital mortality rates but does
reduce the incidence of ICU-acquired pneumonia and
ICU length of stay [256].
Conclusion
Apart from IBD, IBS, metabolic diseases and intestinal
failure in critically ill patients, other diseases might be re-
lated to the gut microbiota and the intestinal barrier such
as celiac disease [175,176], colon carcinoma [257] orinflammatory joint diseases [258]. Therefore, alteration of
the gut barrier seems to have multiple consequences facili-
tating the onset of a variety of diseases depending on other
hits and on genetic or epigenetic constellations, respect-
ively. The growing significance of the gut barrier and bac-
terial translocation raises the questions of how we can
improve gut barrier functions and gut microbiota.
The research on modulation of gut permeability is just
starting. On the other hand, a few approaches have been
identified among which are dietetic concepts including
prebiotics, as well as probiotics, and possibly also fecal
transplantation that can be regarded as an unspecific and
global probiotic treatment. Indeed, fecal transplantation
now enters clinical medicine, after beneficial effects in pa-
tients with therapy-refractory Clostridium difficile infec-
tion have been reported [259,260]. Apart from this novel
approach, other interventions have been proposed such as
particular diets, prebiotics or probiotics (Table 8). Among
the diets, some sound promising such as dietary restric-
tion of fat and sugars, or possibly also of poorly absorbed
short-chain carbohydrates (FODMAPs) [261-263]. Clearly,
more intervention trials are urgently needed now to asses
the effects of such substances as preventive or therapeutic
agents in different populations and diseases, respectively.
For these trials, not only known substances (see Table 8),
but also new dietetic components and probiotic agents se-
lected according to their beneficial effects on the gut bar-
rier have to be identified and tested.
To conduct such trials in a scientifically sound way, we
need a clear definition and validation of the tools needed
to assess gut barrier functions and intestinal permeability.
New approaches such as mucus analysis, quantification of
translocated bacteria and bacterial products in blood or
tissue, and host responses to such alterations, e.g. liver
steatosis or fat infection by commensal bacteria, need to
be evaluated. Even though European authorities strictly
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modulate intestinal permeability, such as probiotics,
prebiotics or other possibly enriched dietetic compo-
nents, need clear scientific evaluation independent of
their legal classification, which can be questioned from
a scientific point of view [264,265]. The fact that such
substances can be used both for prevention of disease
in the general population and for prophylaxis or treat-
ment of disease in defined subpopulations and thus
touch both legal categories of substances, a third cat-
egory should be considered placed between the two
existing ones. This new category could be named for
example “functional food” usable for both healthy nu-
trition and medical intervention and requiring trials
based on elements established in part in the health
claim regulations and in part in the drug laws. A polit-
ical effort to establish such a new “functional food” cat-
egory in the European legislation, similar to the one
existing in Japan, would support more scientific efforts
as well as substantial business efforts to develop this
new exiting area of health research further.
Despite many open questions, intestinal permeability
becomes an area of growing interest both in basic sci-
ence and for clinicians, because it might by a valuable
new target for disease prevention and therapy. The ex-
pert panel agreed on several conclusions:
 Definition of intestinal permeability and intestinal
barrier (see Table 1).
 Assessment of intestinal permeability and intestinal
barrier (see Tables 4 and 5).
 Given the importance of the physiological and thus
the clinical role of the intestinal permeability there is
a need for biomarkers that not only reflect lost
functionality of the intestine, but also permeability
per se and permeability-related functions such as
mucus quality. More research is needed to develop
reliable non-invasive, rapid diagnostic means.
 The role of microbiota in the regulation of intestinal
permeability also requires additional research.
 Food intake is of importance for the intestinal
microbiota composition as well as for intestinal
permeability, but to which extent? Apart from
dietetic approaches, what else can attenuate negative
effects of nutrients? What is the preventive capacity
of pre- and probiotics?
 The question of how to define a healthy microbiota
needs to be addressed. Can an "unhealthy
microbiota" affect intestinal permeability in a
negative way?
 Are changes in intestinal microbiota in diseases such
as IBS or IBD cause or effect of the disease? Can an
"unhealthy" intestinal microbiota impair the mucosal
immune system through an excessively permeablemucosal barrier, and thus perturb bowel physiology
and sensory perception?
 Can we look at the intestinal microbiota as a novel
therapeutic tool to improve intestinal permeability
and gut health?
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